{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:43:57Z","timestamp":1791150237076,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,14]]},"DOI":"10.7759\/cureus.101519","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:50:26Z","timestamp":1768398626000},"source":"Crossref","is-referenced-by-count":1,"title":["Cardiac Valvular Incompetence Associated With Selective Serotonin Reuptake Inhibitors (SSRIs): A Disproportionality and Risk Factor Analysis From Global Safety Reports"],"prefix":"10.7759","author":[{"given":"Adrian Chin Yan","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Selective serotonin reuptake inhibitors","author":"Chu A","year":"2023","unstructured":"Chu A, Wadhwa R. Selective serotonin reuptake inhibitors. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff AN","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA, et al.. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021, 13:387-401. 10.3390\/neurolint13030038","journal-title":"Neurol Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-001-0986-x","article-title":"Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex","volume":"160","author":"Bymaster FP","year":"2002","unstructured":"Bymaster FP, Zhang W, Carter PA, et al.. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002, 160:353-61. 10.1007\/s00213-001-0986-x","journal-title":"Psychopharmacology (Berl)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01285-w","article-title":"The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review","volume":"27","author":"S\u00f8rensen A","year":"2022","unstructured":"S\u00f8rensen A, Ruh\u00e9 HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review. Mol Psychiatry. 2022, 27:192-201. 10.1038\/s41380-021-01285-w","journal-title":"Mol Psychiatry"},{"key":"ref5","article-title":"Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond","volume":"65 Suppl 4","author":"Owens MJ","year":"2004","unstructured":"Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry. 2004, 65 Suppl 4:5-10.","journal-title":"J Clin Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: an update","volume":"38","author":"Elangbam CS","year":"2010","unstructured":"Elangbam CS. Drug-induced valvulopathy: an update. Toxicol Pathol. 2010, 38:837-48. 10.1177\/0192623310378027","journal-title":"Toxicol Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2174\/15680266113139990039","article-title":"Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease","volume":"13","author":"Reid TE","year":"2013","unstructured":"Reid TE, Kumar K, Wang XS. Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease. Curr Top Med Chem. 2013, 13:1353-62. 10.2174\/15680266113139990039","journal-title":"Curr Top Med Chem"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2013.02.003","article-title":"Drug-induced valvular heart disease: an update","volume":"106","author":"Andrejak M","year":"2013","unstructured":"Andrejak M, Tribouilloy C. Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis. 2013, 106:333-9. 10.1016\/j.acvd.2013.02.003","journal-title":"Arch Cardiovasc Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2009.05.002","article-title":"Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography","volume":"22","author":"Smith SA","year":"2009","unstructured":"Smith SA, Waggoner AD, de las Fuentes L, Davila-Roman VG. Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J Am Soc Echocardiogr. 2009, 22:883-9. 10.1016\/j.echo.2009.05.002","journal-title":"J Am Soc Echocardiogr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-314403","article-title":"Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis","volume":"105","author":"Fortier JH","year":"2019","unstructured":"Fortier JH, Pizzarotti B, Shaw RE, Levy RJ, Ferrari G, Grau J. Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis. Heart. 2019, 105:1140-8. 10.1136\/heartjnl-2018-314403","journal-title":"Heart"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvx092","article-title":"Serotonin and catecholamines in the development and progression of heart valve diseases","volume":"113","author":"Goldberg E","year":"2017","unstructured":"Goldberg E, Grau JB, Fortier JH, Salvati E, Levy RJ, Ferrari G. Serotonin and catecholamines in the development and progression of heart valve diseases. Cardiovasc Res. 2017, 113:849-57. 10.1093\/cvr\/cvx092","journal-title":"Cardiovasc Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X12666140828221720","article-title":"Fluoxetine and all other SSRIs are 5-HT2B agonists - importance for their therapeutic effects","volume":"12","author":"Peng L","year":"2014","unstructured":"Peng L, Gu L, Li B, Hertz L. Fluoxetine and all other SSRIs are 5-HT2B agonists - importance for their therapeutic effects. Curr Neuropharmacol. 2014, 12:365-79. 10.2174\/1570159X12666140828221720","journal-title":"Curr Neuropharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2081","article-title":"Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension","volume":"144","author":"Sadoughi A","year":"2013","unstructured":"Sadoughi A, Roberts KE, Preston IR, Lai GP, McCollister DH, Farber HW, Hill NS. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest. 2013, 144:531-41. 10.1378\/chest.12-2081","journal-title":"Chest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4021\/jocmr654w","article-title":"Effect of serotonin reuptake inhibitors on pulmonary hemodynamics in humans","volume":"3","author":"Pleym H","year":"2011","unstructured":"Pleym H, Greiff G, Mjorndal T, Stenseth R, Wahba A, Spigset O. Effect of serotonin reuptake inhibitors on pulmonary hemodynamics in humans. J Clin Med Res. 2011, 3:230-8. 10.4021\/jocmr654w","journal-title":"J Clin Med Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2015.1125563","article-title":"A happy valve in a happy patient? Serotonergic antidepressants and the risk of valvular heart disease (SERVAL). A case-control study","volume":"71","author":"De Backer T","year":"2016","unstructured":"De Backer T, Petrovic M, Audenaert K, Coeman M, De Bacquer D. A happy valve in a happy patient? Serotonergic antidepressants and the risk of valvular heart disease (SERVAL). A case-control study. Acta Clin Belg. 2016, 71:57-62. 10.1080\/17843286.2015.1125563","journal-title":"Acta Clin Belg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfae152","article-title":"Application of a quantitative uncertainty assessment to develop ranges of plausible toxicity values when using observational data in risk assessment: a case study examining associations between PFOA and PFOS exposures and vaccine response","volume":"204","author":"Wikoff DS","year":"2025","unstructured":"Wikoff DS, Vincent MJ, Heintz MM, Pastula ST, Reichert H, Klaren WD, Haws LC. Application of a quantitative uncertainty assessment to develop ranges of plausible toxicity values when using observational data in risk assessment: a case study examining associations between PFOA and PFOS exposures and vaccine response. Toxicol Sci. 2025, 204:96-115. 10.1093\/toxsci\/kfae152","journal-title":"Toxicol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19063264","article-title":"Inconsistent country-wide reporting of adverse drug reactions to antimicrobials in Sierra Leone (2017-2021): a wake-up call to improve reporting","volume":"19","author":"Thomas F","year":"2022","unstructured":"Thomas F, Abiri OT, Komeh JP, et al.. Inconsistent country-wide reporting of adverse drug reactions to antimicrobials in Sierra Leone (2017-2021): a wake-up call to improve reporting. Int J Environ Res Public Health. 2022, 19:3264. 10.3390\/ijerph19063264","journal-title":"Int J Environ Res Public Health"},{"key":"ref18","unstructured":"ATC\/DDD Index. (2025). https.\/\/atcddd.fhi.no\/atc_ddd_index\/."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.18178\/jtle.4.2.128-134","article-title":"Logistic regression with missing data: a comparison of handling methods, and effects of percent missing values","volume":"2","author":"Meeyai S","year":"2016","unstructured":"Meeyai S. Logistic regression with missing data: a comparison of handling methods, and effects of percent missing values. J Traffic Logist Eng. 2016, 2:10.18178\/jtle.4.2.128-134","journal-title":"J Traffic Logist Eng"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.08.032","article-title":"A meta-analysis on the association between SSRIs and blood pressure in patients with CVD and depression","volume":"340","author":"Zhang L","year":"2023","unstructured":"Zhang L, Li G, Liu M. A meta-analysis on the association between SSRIs and blood pressure in patients with CVD and depression. J Affect Disord. 2023, 340:181-8. 10.1016\/j.jad.2023.08.032","journal-title":"J Affect Disord"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003172","article-title":"Antidepressants and valvular heart disease: a nested case-control study in Taiwan","volume":"95","author":"Lin CH","year":"2016","unstructured":"Lin CH, Hsiao FY, Liu YB, Gau SS, Wang CC, Shen LJ. Antidepressants and valvular heart disease: a nested case-control study in Taiwan. Medicine (Baltimore). 2016, 95:e3172. 10.1097\/MD.0000000000003172","journal-title":"Medicine (Baltimore)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015786","article-title":"Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: a network meta-analysis of randomized controlled trials","volume":"98","author":"Guo S","year":"2019","unstructured":"Guo S, Chen L, Cheng S, Xu H. Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: a network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019, 98:e15786. 10.1097\/MD.0000000000015786","journal-title":"Medicine (Baltimore)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201500098","article-title":"Bayesian model selection in logistic regression for the detection of adverse drug reactions","volume":"58","author":"Marbac M","year":"2016","unstructured":"Marbac M, Tubert-Bitter P, Sedki M. Bayesian model selection in logistic regression for the detection of adverse drug reactions. Biom J. 2016, 58:1376-89. 10.1002\/bimj.201500098","journal-title":"Biom J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.30773\/pi.2022.0209","article-title":"Confounding by indication in studies of selective serotonin reuptake inhibitors","volume":"19","author":"Lee J","year":"2022","unstructured":"Lee J, Chang SM. Confounding by indication in studies of selective serotonin reuptake inhibitors. Psychiatry Investig. 2022, 19:873-83. 10.30773\/pi.2022.0209","journal-title":"Psychiatry Investig"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15090443","article-title":"Future of valvular heart disease and structural heart interventions: why so much excitement?","volume":"15","author":"Beneki E","year":"2025","unstructured":"Beneki E, Grapsa J. Future of valvular heart disease and structural heart interventions: why so much excitement?. J Pers Med. 2025, 15:443. 10.3390\/jpm15090443","journal-title":"J Pers Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/453890-cardiac-valvular-incompetence-associated-with-selective-serotonin-reuptake-inhibitors-ssris-a-disproportionality-and-risk-factor-analysis-from-global-safety-reports","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:50:27Z","timestamp":1768398627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/453890-cardiac-valvular-incompetence-associated-with-selective-serotonin-reuptake-inhibitors-ssris-a-disproportionality-and-risk-factor-analysis-from-global-safety-reports"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.101519","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,14]]}}}